Zobrazeno 1 - 10 of 19 pro vyhledávání: '"Brian T. Burgess"'
1
Akademický článek
Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant BRCA1 Mutant Ovarian Cells
Autor: Brian T. Burgess, Abigail M. Anderson, J. Robert McCorkle, Jianrong Wu, Frederick R. Ueland, Jill M. Kolesar
Publikováno v: Diagnostics, Vol 10, Iss 2, p 121 (2020)
Objective: Despite the promise of PARP inhibitors (PARPi) for treating BRCA1/2 mutated ovarian cancer (OC), drug resistance invariably develops. We hypothesized rationale drug combinations, targeting key molecules in DNA repair pathways and the cell
Externí odkaz: https://doaj.org/article/719bebe97d414206880c0a4241d77a68
Zobrazit plný text záznamu
2
Akademický článek
Disease-Specific Survival of Type I and Type II Epithelial Ovarian Cancers—Stage Challenges Categorical Assignments of Indolence & Aggressiveness
Autor: Edward J. Pavlik, Christopher Smith, Taylor S. Dennis, Elizabeth Harvey, Bin Huang, Quan Chen, Dava West Piecoro, Brian T. Burgess, Anthony McDowell, Justin Gorski, Lauren A. Baldwin, Rachel W. Miller, Christopher P. DeSimone, Charles Dietrich, Holly H. Gallion, Frederick R. Ueland, John R. van Nagell
Publikováno v: Diagnostics, Vol 10, Iss 2, p 56 (2020)
Epithelial ovarian cancers (EOC) consist of several sub-types based on histology, clinical, molecular and epidemiological features that are termed “histo-types”, which can be categorized into less aggressive Type I and more aggressive Type II mal
Externí odkaz: https://doaj.org/article/8d29c184173246eeae91ac8f3552118c
Zobrazit plný text záznamu
3
Akademický článek
Clinical Factors Associated with Longer Hospital Stay Following Ovarian Cancer Surgery
Autor: Christopher G. Smith, Daniel L. Davenport, Justin Gorski, Anthony McDowell, Brian T. Burgess, Tricia I. Fredericks, Lauren A. Baldwin, Rachel W. Miller, Christopher P. DeSimone, Charles S. Dietrich, Holly H. Gallion, Edward J. Pavlik, John R. van Nagell, Frederick R. Ueland
Publikováno v: Healthcare, Vol 7, Iss 3, p 85 (2019)
Background: Ovarian cancer (OC) is the leading cause of death from gynecologic malignancy and is treated with a combination of cytoreductive surgery and platinum-based chemotherapy. Extended length of stay (LOS) after surgery can affect patient morbi
Externí odkaz: https://doaj.org/article/eeb11e32ce1d433082c2bf6d097393a3
Zobrazit plný text záznamu
5
Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant BRCA1 Mutant Ovarian Cells
Autor: Jill M. Kolesar, Abigail Anderson, Brian T. Burgess, J. Robert McCorkle, Jianrong Wu, Frederick R. Ueland
Publikováno v: Diagnostics, Vol 10, Iss 2, p 121 (2020)
Diagnostics
Volume 10
Issue 2
Objective: Despite the promise of PARP inhibitors (PARPi) for treating BRCA1/2 mutated ovarian cancer (OC), drug resistance invariably develops. We hypothesized rationale drug combinations, targeting key molecules in DNA repair pathways and the cell
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2857d1553189ec41f6554f58b25f8ac4
https://www.mdpi.com/2075-4418/10/2/121
Zobrazit plný text záznamu
7
Survival of Women With Type I and II Epithelial Ovarian Cancer Detected by Ultrasound Screening
Autor: Christopher P. DeSimone, Frederick R. Ueland, John R. van Nagell, Bin Huang, Brian T. Burgess, Rachel W. Miller, Edward J. Pavlik, Quan Chen, Richard J. Kryscio, Lauren A. Baldwin
Publikováno v: Obstet Gynecol
To estimate the effect of ultrasound screening on stage at detection and long-term disease-specific survival of at-risk women with epithelial ovarian cancer.Eligibility included all asymptomatic women 50 years of age or older and women 25 years of ag
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa8b6bcdcff0ee9744637857997fc66e
https://doi.org/10.1097/aog.0000000000002921
Zobrazit plný text záznamu
8
Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant
Autor: Brian T, Burgess, Abigail M, Anderson, J Robert, McCorkle, Jianrong, Wu, Frederick R, Ueland, Jill M, Kolesar
Publikováno v: Diagnostics
Objective: Despite the promise of PARP inhibitors (PARPi) for treating BRCA1/2 mutated ovarian cancer (OC), drug resistance invariably develops. We hypothesized rationale drug combinations, targeting key molecules in DNA repair pathways and the cell
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::ffd71723a6a1883b06de75d100a11233
https://pubmed.ncbi.nlm.nih.gov/32098452
Zobrazit plný text záznamu
9
Adnexal tumors in menopausal women: surgery or surveillance?
Autor: Brian T. Burgess, Frederick R. Ueland
Publikováno v: Menopause. 26:554-556
Asymptomatic ovarian tumors in menopausal women do not always require surgical removal. Experts recommend an initial evaluation with transvaginal ultrasound to help characterize the tumor's malignant risk. Low-risk tumors can be monitored with ultras
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eee4b56f9e2ef5e4650837293d222d39
https://doi.org/10.1097/gme.0000000000001330
Zobrazit plný text záznamu
10
Abstract B22: Development of the first ovarian carcinosarcoma patient-derived xenograft and tissue organoid model to predict clinical response to chemotherapy
Autor: Jill M. Kolesar, Frederick R. Ueland, Anthony McDowell, Jodi M. DeJohn, Joseph R. McCorkle, Justin W. Gorski, Brian T. Burgess, Christopher P. DeSimone
Publikováno v: Clinical Cancer Research. 26:B22-B22
Objectives: Ovarian carcinosarcoma is an unusual and aggressive form of ovarian cancer. Due to the rarity of the disease, little empirical evidence exists about the efficacy of different chemotherapeutic regimens. Thus, the objective of this research
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::448f2799aa5fda7645beb44a69265593
https://doi.org/10.1158/1557-3265.ovca19-b22
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje